A larger patient volume, coupled with staffing shortages, could bring on a crisis in advanced disease care across the board. Add to this persistent supply chain issues, manufacturing labor shortages, and shipping disruptions, and you have a perfect storm that could mean greater risks to patient care.

Some 50% of Americans don’t take their medications as directed by their doctor, for any of a host of reasons. This non-adherence leads to preventable hospitalizations and preventable deaths, and costs 16% or $500 billion of the entire U.S. healthcare spend every year.

The new CDC draft removes the 2016 recommended ceilings on prescription doses for chronic pain patients and instead encourages doctors to exercise their best judgment. Even though the previous dosing ceilings were recommendations, they led to unintended consequences: States codified them, and physicians concerned with criminal or civil penalties misapplied the rigid standards by tapering patients too quickly or even refusing to provide treatment.

Since 2020, the healthcare industry has lost nearly half a million workers, exacerbating staffing shortages that existed prior to the start of the pandemic. One of the hardest-hit areas is the pharmacy. As of September 2021, the U.S. Bureau of Labor Statistics projected there would be 43,000 pharmacist and pharmacy technician job openings each year throughout the next decade.

Clinical trials are expensive, take significant time, and can run into any number of challenges and delays. The average drug study will see a 30% patient dropout rate. What is needed, according to Virginia-based Jeeva Informatics, is more diverse patient enrollment, better engagement, and increased evidence generation.

Pharmacies need a streamlined clinical and operational option to integrate data and deliver actionable analytics in one place rather than across disparate sources. This is particularly important in infection prevention and antimicrobial stewardship programs, where providers need to identify indications, treatment options, resistance considerations, potential drug interactions, and pharmacology.

Medication non-adherence, particularly among senior patients, is a costly problem facing the American healthcare system. This issue results in an estimated $100 billion–$290 billion in annual costs, according to studies reviewed in the Annals of Internal Medicine (AIM). Other research cited by AIM indicates that 20%–30% of prescribed medications go unfilled by patients and approximately 50% of medications for chronic diseases aren’t used by patients as prescribed.

Healthcare organizations, whose staff are continuing to feel the stress of COVID-19, will need to double down on diversion prevention strategies in the coming months to avoid serious legal, financial, and clinical consequences, from massive monetary fines to the spread of healthcare-acquired infections such as hepatitis C.